Dominant Negative Scleraxis Mutant for Fibrosis Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively modulate the expression of scleraxis protein and collagen synthesis in mammalian tissues, leading to excessive fibrosis and impaired tissue function, particularly in cardiac tissues following injuries or prolonged physiological stresses like hypertension.
Innovation Solution
Development of a basic domain deletion mutant of the scleraxis protein (ScxΔBD) that acts as an antagonist to scleraxis protein expression and collagen synthesis, utilizing nucleotide sequences with at least 75% homology to the wild-type scleraxis sequence, to inhibit the activation and accumulation of scleraxis and COL1α2 genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If scleraxis protein levels are increased in damaged tissues, then wound healing and fibroblast activation are promoted, but excessive fibrosis and scar tissue formation occur leading to impaired tissue function
Solution Approach 1:
The patent introduces a dominant negative scleraxis mutant protein as an intermediary that binds to TGF-β1 signaling components and COL1α2 gene promoter regions, blocking the harmful effects of endogenous scleraxis while allowing controlled wound healing. This intermediary protein acts as a molecular decoy that prevents excessive fibrosis without completely abolishing wound repair mechanisms.
Solution Approach 2:
The invention changes the functional parameters of scleraxis protein by creating a mutant version with altered DNA binding affinity and transcriptional activation capability. The dominant negative mutant has modified parameters that allow it to bind to target sequences but prevent productive transcription, thereby controlling the level and timing of collagen expression to avoid excessive fibrosis.
2Reliability
If TGF-β1 signaling is activated to promote fibroblast phenoconversion, then wound healing is enhanced, but scleraxis overexpression and collagen overproduction occur causing fibrosis
Solution Approach 1:
The patent applies preliminary anti-action by introducing the dominant negative scleraxis mutant before excessive collagen production occurs. The mutant protein pre-occupies TGF-β1 signaling pathways and COL1α2 promoter regions, preventing the cascade that would lead to pathological collagen overproduction while still allowing initial wound healing responses to proceed.
3Ease of operation
If current therapies are used to modulate fibrosis, then some symptomatic relief is achieved, but effective modulation of scleraxis expression and collagen synthesis is not attained
Solution Approach 1:
The patent extracts the problematic DNA binding domain from the scleraxis protein to create a dominant negative mutant. This extracted approach allows the mutant to interfere with endogenous scleraxis function without requiring complete scleraxis elimination, providing a more nuanced and effective therapeutic mechanism that specifically targets pathological fibrosis while preserving essential wound healing functions.
Data Source
AI summary
Compositions and kits for modulating expression of scleraxis and/or collagen synthesis in mammalian cells and tissues. The compositions and kits comprise a protein comprising an amino acid sequence that shares at least 75% homology with SEQ ID NO:11. Proteins comprising amino acid sequences that share at least 75% homology with SEQ ID NO: 11 are expressed by mutants of scleraxis gene wherein a nucleotide sequence comprising a basic DNA binding domain has been deleted. Such mutants are exemplified by basic domain deletion ScxΔBD mutants that comprise nucleotide sequences sharing at least 75% homology with SEQ ID NO:8 or SEQ ID NO: 10. Methods for modulating fibrosis in a subject comprising administration of a composition comprising at least one physiologically effective dosage of a protein comprising a polypeptide molecule comprising an amino acid sequence that shares at least 75% homology with SEQ ID NO: 11.